Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Natural history of multiple system atrophy in the USA: a prospective cohort study.

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J.

Lancet Neurol. 2015 Jul;14(7):710-9. doi: 10.1016/S1474-4422(15)00058-7. Epub 2015 May 27.

2.

Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease.

Bronstein JM, Paul K, Yang L, Haas RH, Shults CW, Le T, Ritz B.

Mov Disord. 2015 May;30(6):862-6. doi: 10.1002/mds.26164. Epub 2015 Mar 11.

3.

Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure.

Lipp A, Sandroni P, Ahlskog JE, Fealey RD, Kimpinski K, Iodice V, Gehrking TL, Weigand SD, Sletten DM, Gehrking JA, Nickander KK, Singer W, Maraganore DM, Gilman S, Wenning GK, Shults CW, Low PA.

Arch Neurol. 2009 Jun;66(6):742-50. doi: 10.1001/archneurol.2009.71.

4.

Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons.

Meurers BH, Dziewczapolski G, Shi T, Bittner A, Kamme F, Shults CW.

J Neurosci. 2009 May 27;29(21):6828-39. doi: 10.1523/JNEUROSCI.5310-08.2009.

5.

Dopamine depletion induced up-regulation of HCN3 enhances rebound excitability of basal ganglia output neurons.

Meurers BH, Dziewczapolski G, Bittner A, Shi T, Kamme F, Shults CW.

Neurobiol Dis. 2009 Apr;34(1):178-88.

PMID:
19320057
6.

Clinical correlates of depressive symptoms in familial Parkinson's disease.

Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study Group-PROGENI Investigators.

Mov Disord. 2008 Nov 15;23(15):2216-23. doi: 10.1002/mds.22285.

7.

Potential outcome measures and trial design issues for multiple system atrophy.

May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW; North American Multiple System Atrophy Study Group.

Mov Disord. 2007 Dec;22(16):2371-7.

8.

LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.

Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T; Parkinson Study Group-PROGENI Investigators.

Neurology. 2007 Oct 30;69(18):1737-44. Epub 2007 Sep 5.

PMID:
17804834
9.

Calf venous compliance in multiple system atrophy.

Lipp A, Sandroni P, Ahlskog JE, Maraganore DM, Shults CW, Low PA.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H260-5. Epub 2007 Mar 2.

10.

G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy.

Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW; North American Multiple System Atrophy Study Group.

Mov Disord. 2007 Mar 15;22(4):546-9.

11.

R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation.

Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T; Parkinson Study Group - PROGENI Investigators.

Mov Disord. 2007 Jan 15;22(2):254-7.

PMID:
17149721
12.

Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC; Parkinson Study Group-PROGENI Investigators.

Mov Disord. 2006 Dec;21(12):2257-60.

PMID:
17078063
13.

Mutations in DJ-1 are rare in familial Parkinson disease.

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC; Parkinson Study Group - PROGENI Investigators.

Neurosci Lett. 2006 Nov 20;408(3):209-13. Epub 2006 Sep 25.

14.

alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy.

Shults CW, Barrett JM, Fontaine D.

Neurosci Lett. 2006 Sep 25;405(3):223-5. Epub 2006 Aug 9.

PMID:
16901642
15.

Clinical trials of coenzyme Q10 in neurological disorders.

Shults CW, Haas R.

Biofactors. 2005;25(1-4):117-26. Review. No abstract available.

PMID:
16873936
16.

Lewy bodies.

Shults CW.

Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1661-8. Epub 2006 Jan 31.

17.

Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E.

J Neurosci. 2005 Nov 16;25(46):10689-99.

18.

The North American Multiple System Atrophy Study Group.

Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T; North American Multiple System Atrophy Study Group.

J Neural Transm (Vienna). 2005 Dec;112(12):1687-94. Review.

19.

Mitochondrial dysfunction and possible treatments in Parkinson's disease--a review.

Shults CW.

Mitochondrion. 2004 Sep;4(5-6):641-8. Epub 2004 Sep 29.

PMID:
16120421
20.

Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia.

Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC.

Mov Disord. 2006 Jan;21(1):45-9.

PMID:
16116614
21.

Reexamination of the TEMPO Study.

Shults CW.

Arch Neurol. 2005 Aug;62(8):1320; author reply 1321. No abstract available.

PMID:
16087778
22.

Therapeutic role of coenzyme Q(10) in Parkinson's disease.

Shults CW.

Pharmacol Ther. 2005 Jul;107(1):120-30. Epub 2005 Apr 21. Review.

PMID:
15963354
23.

Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death.

Tsuboi K, Grzesiak JJ, Bouvet M, Hashimoto M, Masliah E, Shults CW.

Mol Cell Neurosci. 2005 Jun;29(2):259-68.

PMID:
15911350
24.

Antioxidants as therapy for Parkinson's disease.

Shults CW.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):694-700. Review. No abstract available.

PMID:
15890014
25.

Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T; Parkinson Study Group-PROGENI investigators.

Lancet. 2005 Jan 29-Feb 4;365(9457):410-2.

PMID:
15680455
26.

The role of radiotracer imaging in Parkinson disease.

Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R.

Neurology. 2005 Jan 25;64(2):208-15. Review.

PMID:
15668415
27.

Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).

Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group.

Mov Disord. 2004 Dec;19(12):1391-402.

PMID:
15452868
28.

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.

Shults CW, Flint Beal M, Song D, Fontaine D.

Exp Neurol. 2004 Aug;188(2):491-4.

PMID:
15246848
29.

Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease.

Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T; Parkinson Study Group.

Mov Disord. 2004 Jun;19(6):649-55.

PMID:
15197702
30.

Measuring the effects of therapy in Parkinson disease.

Shults CW, Haas R, Oakes D, Kieburtz K, Plumb S, Shoulson I, Beal MF, Juncos J, Nutt J.

JAMA. 2004 May 26;291(20):2430-1; author reply 2431. No abstract available.

PMID:
15161889
31.

Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci.

Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC; Parkinson Study Group.

Neurology. 2004 May 11;62(9):1616-8.

PMID:
15136695
32.

Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E.

Exp Neurol. 2004 Apr;186(2):158-72.

PMID:
15026254
33.

Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease.

Beal MF, Shults CW.

Biofactors. 2003;18(1-4):153-61. Review. No abstract available.

PMID:
14695931
34.

Treatments of Parkinson disease: circa 2003.

Shults CW.

Arch Neurol. 2003 Dec;60(12):1680-4. Review.

PMID:
14676041
35.

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ.

Exp Neurol. 2003 Nov;184 Suppl 1:S68-79. Review.

PMID:
14597329
36.

Survival and differentiation of adult rat-derived neural progenitor cells transplanted to the striatum of hemiparkinsonian rats.

Dziewczapolski G, Lie DC, Ray J, Gage FH, Shults CW.

Exp Neurol. 2003 Oct;183(2):653-64.

PMID:
14552907
37.

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families.

Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T; Parkinson Study Group.

Hum Mol Genet. 2003 Oct 15;12(20):2599-608. Epub 2003 Aug 12.

PMID:
12925570
38.

Coenzyme Q10 in neurodegenerative diseases.

Shults CW.

Curr Med Chem. 2003 Oct;10(19):1917-21. Review.

PMID:
12871093
39.

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group.

Arch Neurol. 2002 Oct;59(10):1541-50.

PMID:
12374491
40.

The adult substantia nigra contains progenitor cells with neurogenic potential.

Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH.

J Neurosci. 2002 Aug 1;22(15):6639-49.

41.

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E.

J Neurosci Res. 2002 Jun 1;68(5):568-78.

PMID:
12111846
42.
43.

A cue to queue for CoQ?

Shults CW, Schapira AH.

Neurology. 2001 Aug 14;57(3):375-6. No abstract available.

PMID:
11502896
44.

Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine.

Shults CW, Ray J, Tsuboi K, Gage FH.

Brain Res. 2000 Nov 17;883(2):192-204.

PMID:
11074048
45.

Image motion and context: a between- and within-subjects comparison.

Simons RF, Detenber BH, Reiss JE, Shults CW.

Psychophysiology. 2000 Sep;37(5):706-10.

PMID:
11037047
46.

Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion.

Tsuboi K, Kimber TA, Shults CW.

Brain Res. 2000 Jun 2;866(1-2):55-64.

PMID:
10825480
47.

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.

Shults CW, Haas RH, Beal MF.

Biofactors. 1999;9(2-4):267-72. Review.

PMID:
10416040
48.
49.

Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients.

Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH.

Neurology. 1998 Mar;50(3):793-5.

PMID:
9521279
50.

Supplemental Content

Loading ...
Support Center